Tarsus Pharmaceuticals (TARS) Other Non-Current Assets (2019 - 2026)

Tarsus Pharmaceuticals' Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• In Q1 2026, Other Non-Current Assets fell 21.93% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $2.0 million (down 21.93% YoY), while the FY2025 annual figure was $1.9 million, down 27.36% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $2.0 million, up from $1.9 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $2.6 million in Q1 2025, with the low at $529000.0 in Q1 2023.
• The 5-year median for Other Non-Current Assets is $1.2 million (2025), against an average of $1.3 million.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets sank 63.9% in 2022, then soared 158.8% in 2023.
• Tarsus Pharmaceuticals' Other Non-Current Assets stood at $585000.0 in 2022, then surged by 158.8% to $1.5 million in 2023, then soared by 69.22% to $2.6 million in 2024, then dropped by 27.36% to $1.9 million in 2025, then gained by 7.52% to $2.0 million in 2026.
• Business Quant data shows TARS's Other Non-Current Assets at $2.0 million in Q1 2026, $1.9 million in Q4 2025, and $1.2 million in Q3 2025.